2-(4-溴-2-氯苯基)乙醇 | 916516-90-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-溴-2-氯苯基)乙醇
• 英文名称: 2-(4-Bromo-2-chlorophenyl)ethanol
• CAS: 916516-90-0
• 化学式: C₈H₈BrClO
• 分子量: 235.5
• InChiKey: WAUUNSIHRYKSEY-UHFFFAOYSA-N

物化性质

• 沸点：
  304.1±27.0 °C(Predicted)
• 密度：
  1.592±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于二氯甲烷、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  (S)-ethyl 3-(benzyloxycarbonylamino)-3-(3-((4-bromo-2-methylphenethoxy)carbonylamino)phenyl)propanoate 、 tert-butyl 3-isocyanatobenzylcarbamate 、 2-(4-溴-2-氯苯基)乙醇 以to give 61D (1.84 g, 50%) as an oil的产率得到4-(2-(3-((tert-butoxycarbonylamino)methyl)phenylcarbamoyloxy)ethyl)-3-chlorophenylbromide
  参考文献：
  名称：

  MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

  摘要：

  本发明涉及一般的新型大环化合物，其化学式为（I）或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中变量A、B、L、M、W、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如本文中所定义。这些化合物是选择性抑制剂凝血因子VIIa的丝氨酸蛋白酶，可用作药物。

  公开号：

  US20090281139A1
• 作为产物：
  描述：

  2-(4-bromo-2-methylphenyl)ethanol 、 2-chloro-4-bromostyrene 、 9-硼双环[3.3.1]壬烷 反应 10.0h， 以to yield 61B (2.9 g, 54%) as an oil的产率得到2-(4-溴-2-氯苯基)乙醇
  参考文献：
  名称：

  MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

  摘要：

  本发明涉及一般的新型大环化合物，其化学式为（I）或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中变量A、B、L、M、W、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如本文中所定义。这些化合物是选择性抑制剂凝血因子VIIa的丝氨酸蛋白酶，可用作药物。

  公开号：

  US20090281139A1

文献信息

• [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS
  申请人：COURTNEY STEPHEN MARTIN

  公开号：WO2013033085A1

  公开（公告）日：2013-03-07

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化学实体。还提供了包括至少一种化学实体和一种或多种药用载体的药物组合物。描述了治疗对KMO活性抑制敏感的某些疾病和疾病的方法，包括向这些患者投与至少一种化学实体的有效量以减轻疾病或疾病症状的方法。这些疾病包括亨廷顿病等神经退行性疾病。还描述了治疗方法，包括单独使用至少一种化学实体或将至少一种化学实体与一种或多种其他治疗剂结合使用的方法。还提供了筛选能够抑制KMO活性的化合物的方法。
• 2-Aminobutanol Compound and Use Thereof for Medical Purposes
  申请人：Kiuchi Masatoshi

  公开号：US20090082311A1

  公开（公告）日：2009-03-26

  The present invention provides a novel compound having few side effects such as bradycardia and the like and having superior peripheral blood lymphocyte-decreasing effect. The present invention provides a 2-aminobutanol compound represented by the following formula (I) wherein R 1 is a hydrogen atom or P(═O) (OH) 2 , R 2 is an alkyl having 1 to 4 carbon atoms optionally substituted by hydroxyl group(s) or optionally substituted by halogen atom(s), R 3 is a hydrogen atom; a halogen atom; cyano; an alkyl having 1 to 4 carbon atoms optionally substituted by halogen atom(s); or an acyl having 2 to 5 carbon atoms optionally substituted by halogen atom(s), X is an oxygen atom, a sulfur atom, carbonyl or NR 4 wherein R 4 is a hydrogen atom or an alkyl having 1 to 4 carbon atoms, Ar 1 is an optionally substituted arylene or an optionally substituted heteroarylene, and Ar 2 is an optionally substituted aryl or an optionally substituted heteroaryl, provided that when X is an oxygen atom, Ar 1 is phenylene and Ar 2 is phenyl, then the phenyl for Ar 2 should be substituted, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof, as well as a production method of the above-mentioned 2-aminobutanol compound.

  本发明提供了一种新型化合物，具有较少的副作用，如心动过缓等，并具有优越的外周血淋巴细胞降低作用。本发明提供了一种由以下式（I）表示的2-氨基丁醇化合物，其中R1是氢原子或P（═O）（OH）2，R2是1至4个碳原子的烷基，可选地被羟基或卤原子取代，R3是氢原子，卤原子，氰基，1至4个碳原子的烷基，可选地被卤原子取代，或2至5个碳原子的酰基，可选地被卤原子取代，X是氧原子，硫原子，羰基或NR4，其中R4是氢原子或1至4个碳原子的烷基，Ar1是可选取代的芳烃基或可选取代的杂芳烃基，Ar2是可选取代的芳基或可选取代的杂芳基，但当X为氧原子时，Ar1为苯基，Ar2为苯基，则Ar2的苯基应被取代，或其药学上可接受的酸加盐或其水合物或溶剂化物，以及上述2-氨基丁醇化合物的制备方法。
• MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Priestley Eldon Scott

  公开号：US20090281139A1

  公开（公告）日：2009-11-12

  The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, L, M, W, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

  本发明涉及一般的新型大环化合物，其化学式为（I）或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中变量A、B、L、M、W、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如本文中所定义。这些化合物是选择性抑制剂凝血因子VIIa的丝氨酸蛋白酶，可用作药物。
• 2-aminobutanol compound and use thereof for medical purposes
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08114902B2

  公开（公告）日：2012-02-14

  Disclosed is a 2-aminobutanol compound represented by the following formula (I) or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof, as well as a production method of the 2-aminobutanol compound of formula (I). The 2-aminobutanol compounds of formula (I) have few side effects including bradycardia and have superior peripheral blood lymphocyte-decreasing effects.

  本发明公开了一种由以下式（I）表示的2-氨基丁醇化合物，或其药学上可接受的酸加盐或水合物或溶剂化物，以及式（I）的2-氨基丁醇化合物的制备方法。式（I）的2-氨基丁醇化合物具有少量副作用，包括心动过缓，并具有优越的外周血淋巴细胞减少作用。
• 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2017257B1

  公开（公告）日：2014-08-06